Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2008. Net loss for the quarter was $10.5 million, or $0.25 per share, compared to $10.5 million, or $0.34 per share, for the same period in 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

"As we prepare for the unblinding of our Phase 3 data, we find ourselves at a critical inflection point," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The outcome of this trial will not only define the future of our Company but, we believe, could ultimately change the course of treatment for non-Hodgkin's lymphoma patients. If successful, Specifid(TM) (mitumprotimut-T, formerly FavId(R)) would be a groundbreaking cancer therapy, the culmination of nearly a decade of collaboration between our employees, investors, clinical investigators, trial coordinators and patients."

First Quarter 2008 Financial Review

Research and development expense was approximately $8.1 million for the first quarter of 2008, compared to approximately $8.0 million for the same period in 2007. The increase is primarily due to additional operating expenses associated with Favrille's commercial-scale manufacturing facility, stock-based compensation, additional personnel and consulting and outside services to support the Company's Phase 3 registration trial of Specifid, offset by a decrease in manufacturing supplies related to the completion of patient enrollment in the Phase 3 trial and a decrease in cash bonus expense. Total stock-based compensation included in research and development expense was approximately $560,000 for the quarter, compared to approximately $400,000 for the f
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)...estigational sustained follicle stimulant achieves...in beta given over a one week period in Phase III ...ll/ -- Schering-Plough Corp., (NYSE: SGP ) today...cal trial demonstrating that a single injection of...ined follicle stimulants, achieved similar efficac...
(Date:7/1/2009)...ly 1 Peregrine Pharmaceu...t it has been awarded a European patent for a nove... to labels for diagnostic and therapeutic applicat...abeling, was developed for the production of radio...to other agents as well. A study published today ...
(Date:6/30/2009)...summer grass that tickles your feet or the red Bor...of the world around you carries special chemical m...cientists where the molecules that compose a subst...ned to them along the way. But doing these analyse...sts have developed a new method to make isotopic a...
(Date:6/30/2009)...RNewswire-FirstCall/ -- VEGA PROMOTIONAL SYSTEMS, ...osen Chattanooga, TN based consulting firm, Tennes...uilding a biomass production facility in Georgia. ...build a biomass plant in Georgia to take advantage...e,s Bioenergy Corridor. Georgia ranks third in th...
Breaking Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4Stanford researchers find a quicker, cheaper way to sort isotopes 2Stanford researchers find a quicker, cheaper way to sort isotopes 3Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2
...Single-tube amplification method for high-throughp...Beti Belachew Peter Pingerelli ,Melanie Palmer ...uces the HSVision molecular beacon detection,mod...kly detect HSV (herpes simplex virus) DNA. Because...uires no postamplification,manipulation, HSV det...
...High-level expression of heterologous proteins ,... Waesche, Ronda Allen ,Stratagene , Codon bi...ion of,heterologous genes in E. coli hosts. In G...odons (AGG or AGA) and the proline codon (CCC) mos...or such situations, Stratagene introduces,BL21-C...
...High-fidelity PCR of genomic targets up to 19 kb ...uTurbo DNA,Polymerase , Michael Borns Holly...f long targets with PfuTurbo ,DNA polymerase* b...nditions. In this update, we describe adjustments ...ied up to 19 kb in length. , Superior accuracy a...
...tional tools for neuroscience researchers , .... Browning, Mary Ellen Simcox ,Stratagene Clon...ng gene-specific primer sets for the rat and human...ng these primers in reverse,transcriptase-mediat...ow,expression of NMDA subunits with Stratagenes ...
Other Biology Technology:HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex,Virus DNA 2HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex,Virus DNA 3HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex,Virus DNA 4New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 2New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 3New BL21-CodonPlus Cells Correct Codon Bias in GC-Rich Genomes 4Enhanced Amplification of Long Targets with PfuTurbo DNA,Polymerase 2Enhanced Amplification of Long Targets with PfuTurbo DNA,Polymerase 3Gene-Specific Primers for NMDA Receptor Subunits 2Gene-Specific Primers for NMDA Receptor Subunits 3Gene-Specific Primers for NMDA Receptor Subunits 4
(Date:7/1/2009)... European Molecular Biology Laboratory,s European ...a major new e-science resource for biologists whi...1N1 flu and cancer. , Biocatalogue.org , a cent...ces, is being officially launched today (Wednesday...ce on Intelligent Systems for Molecular Biology an...
(Date:7/1/2009)...s from across the United States and Russia are dep... Russian Arctic. The program, known as The Polaris...earch and education, and informing the public abou...Holmes, an associate scientist at the Woods Hole R..., says, "The Arctic is central to the global clima...
(Date:7/1/2009)...first time, scientists have shown that chromosomal... embryos, even those produced by young, fertile co...entre for Human Genetics and the University Fertil...5th annual conference of the European Society of H...July 1), that the surprising finding meant that cu...
(Date:6/30/2009)...e shown that if elderly men were given growth horm... muscle mass increase. Dr. Geoff Goldspink (Royal ...ys: "This raises the question: Can age-related los...eliorated by the therapeutic application of mechan...n also help sufferers of diseases such as muscular...
Breaking Biology News(10 mins):New e-science service could accelerate cancer research 2International team of students and scientists on month-long field course in Siberian Arctic 2International team of students and scientists on month-long field course in Siberian Arctic 3Chromosomal problems affect nearly all human embryos 2Chromosomal problems affect nearly all human embryos 3QUMAS and Datafarm Integration for end to end Electronic Submissions 41869 1QUMAS and Datafarm Integration for end to end Electronic Submissions 41869 2Oncolytics Biotech 28R 29 Inc Announces Positive Results of U K Phase II REOLYSIN 28R 29 and Radiation Combination Clinical Trial 11418 1Oncolytics Biotech 28R 29 Inc Announces Positive Results of U K Phase II REOLYSIN 28R 29 and Radiation Combination Clinical Trial 11418 2Oncolytics Biotech 28R 29 Inc Announces Positive Results of U K Phase II REOLYSIN 28R 29 and Radiation Combination Clinical Trial 11418 3Watson Announces United States Availability of RAPAFLO 28TM 29 28silodosin 29 a Novel New Treatment in Benign Prostatic Hyperplasia 28BPH 29 4134 1Watson Announces United States Availability of RAPAFLO 28TM 29 28silodosin 29 a Novel New Treatment in Benign Prostatic Hyperplasia 28BPH 29 4134 2Watson Announces United States Availability of RAPAFLO 28TM 29 28silodosin 29 a Novel New Treatment in Benign Prostatic Hyperplasia 28BPH 29 4134 3Watson Announces United States Availability of RAPAFLO 28TM 29 28silodosin 29 a Novel New Treatment in Benign Prostatic Hyperplasia 28BPH 29 4134 4Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients 4133 1Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients 4133 2Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients 4133 3Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients 4133 4
...es developed by computer may sound unnerving but t...velopment of new vaccines could bring new products...saving pharmaceutical companies millions of pounds...elling can help scientists to uncover and harness ...in sequences that modern bioscience generates and ...
...c. (Nasdaq: AFFX), announced today the launch of t...iated protocol developed in conjunction with PreAn...daq: QGEN; Frankfurt, Prime Standard: QIA) and BD ...mize the PreAnalytiX PAXgene(TM) Blood RNA System ...prove gene expression profile results of cellular ...
...ian first, UNSW researchers have developed three c...cells. The breakthrough could lead to new treatmen...rd injury. , "This cloning of cells involves a new...ting and then growing a single cell," said UNSW Se...research and is based at the Diabetes Transplant U...
...ass extinction in Earth history some 251 million y... before the main event and was followed by a delay... research by two University of Washington scientis...ygen levels was likely a major reason for both the...ery. , Earth,s land at the time was still massed i...
Other Biology News:Designing vaccines by computer 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3Stem cell research - new cell lines 2Low oxygen likely made Great Dying worse, greatly delayed recovery 2Low oxygen likely made Great Dying worse, greatly delayed recovery 3
...39;s NIS-Elements revolutionizes imaging software ...ntelligence to microscopes, cameras, components an...isualization and achiving tools. Its intuitive int...uisition times while providing powerful features s...
GC-RICH PCR System from Roche Applied Science
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine.
...ens ProteinChip System, Series 4000 incorporates t...nical researchers and biologists in biomarker rese...e, offering the fastest route for converting bioma...me platform. The Series 4000 is designed to fit in...
Biology Products: